Kaitlin joined the Conway Group in January 2024 and is currently working on developing hypoxia-activated prodrugs (HAP-TACs) to degrade target proteins in solid tumors. Her research interests focus on the development of novel small molecule therapeutics to treat human diseases, such as cancer. Previously she worked in inorganic synthesis while at Rutgers University, where she received her B.A. in Chemistry. Outside of the lab, she enjoys photography, fencing, visiting cafes, and exploring LA.